Compare KG & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KG | NSPR |
|---|---|---|
| Founded | N/A | 2005 |
| Country | Bermuda | United States |
| Employees | 44 | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.3M | 72.1M |
| IPO Year | N/A | 2009 |
| Metric | KG | NSPR |
|---|---|---|
| Price | $9.53 | $1.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 10.7K | ★ 100.7K |
| Earning Date | 05-15-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | N/A | $57.98 |
| Revenue Next Year | N/A | $95.41 |
| P/E Ratio | $1.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.07 | $1.04 |
| 52 Week High | $35.37 | $2.93 |
| Indicator | KG | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 23.99 |
| Support Level | $9.90 | N/A |
| Resistance Level | $10.74 | $2.49 |
| Average True Range (ATR) | 0.66 | 0.09 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 34.81 | 22.51 |
Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.